Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.77 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.77 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11615905 | 1.00 | FFAR4 (0.77) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11615881 | 1.00 | FFAR4 (0.77) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11618654 | 1.00 | FFAR4 (0.77) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11613838 | 0.95 | FFAR4 (0.75) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11619689 | 0.95 | FFAR4 (0.75) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11617329 | 0.95 | FFAR4 (0.74) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11613594 | 0.92 | FFAR4 (0.69) | FFAR4FFAR1FAAHGPR84PPARG | |
| SCHEMBL11355705 | 0.92 | FFAR4 (0.67) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL18596323 | 0.92 | FFAR4 (0.67) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL11619500 | 0.90 | FFAR4 (0.96) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4066692-A | 11,12-SECOPROSTAGLANDINS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | claimed |
| US-20020165255-A1 | Osteoporosis compounds | CAMERON KIMBERLY O (US) | 2002-11-07 | — | — | US | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-4097504-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4092356-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4066692-A | 11,12-SECOPROSTAGLANDINS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4059601-A | VASODILATION, HYPOTENSIVE, ANTITHROMBOSIS | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4059602-A | HYPOTENSIVE, VASODILATION, ANTITHROMBOSIS | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-3991087-A | RENAL VASODILATORS, HYPOTENSIVE AGENTS, ANTITHROMBOTICS | MERCK & CO., INC. (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165255-A1 | Osteoporosis compounds | PTGER1, PTGIR, PTGER4 | FFAR4 171/4885FFAR1 180/4885FAAH 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.